Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.
To identify which composite outcome measure most effectively distinguishes active treatments from placebo in randomised controlled trials (RCTs) of biologic or targeted synthetic disease-modifying antirheumatic drugs (b- or tsDMARDs) for psoriatic arthritis (PsA). A systematic l…